2,4-dichloro-N-((4-(cyclopropylmethyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamide

ID: ALA462149

Chembl Id: CHEMBL462149

PubChem CID: 11510618

Max Phase: Preclinical

Molecular Formula: C20H28Cl2N2O3S

Molecular Weight: 447.43

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCS(=O)(=O)N1CCC(CNC(=O)c2ccc(Cl)cc2Cl)(CC2CC2)CC1

Standard InChI:  InChI=1S/C20H28Cl2N2O3S/c1-2-11-28(26,27)24-9-7-20(8-10-24,13-15-3-4-15)14-23-19(25)17-6-5-16(21)12-18(17)22/h5-6,12,15H,2-4,7-11,13-14H2,1H3,(H,23,25)

Standard InChI Key:  BZVQHTBVWLIZLY-UHFFFAOYSA-N

Associated Targets(Human)

SLC6A9 Tchem Glycine transporter 1 (2077 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A5 Tchem Glycine transporter 2 (697 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SLC6A6 Tbio Sodium- and chloride-dependent taurine transporter (65 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Canis familiaris (36305 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 447.43Molecular Weight (Monoisotopic): 446.1198AlogP: 4.35#Rotatable Bonds: 8
Polar Surface Area: 66.48Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 13.40CX Basic pKa: CX LogP: 3.59CX LogD: 3.59
Aromatic Rings: 1Heavy Atoms: 28QED Weighted: 0.64Np Likeness Score: -1.43

References

1. Wolkenberg SE, Zhao Z, Wisnoski DD, Leister WH, O'Brien J, Lemaire W, Williams DL, Jacobson MA, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Gibson C, Ma BK, Polsky-Fisher SL, Lindsley CW, Hartman GD..  (2009)  Discovery of GlyT1 inhibitors with improved pharmacokinetic properties.,  19  (5): [PMID:19181525] [10.1016/j.bmcl.2009.01.015]

Source